AntibioticDosageEffectiveness (%)Resistance rate (%)*Cautions and contraindicationsAdverse effectsCostU.S. Food and Drug Administration pregnancy categoryCommentsInfectious Diseases Society of America recommendation
First-line agents
Fosfomycin (Monurol)3-g packet one time91Up to 0.6Hypersensitivity to fosfomycin, suspected pyelonephritisDiarrhea, headache, nausea, vaginitisNA ($69)BMinimal change in gut flora; effective against methicillin-resistant Staphylococcus aureus, ESBL-producing organisms, Enterococcus faecalis, vancomycin-resistant EnterococcusSingle dose is appropriate for acute cystitis despite concerns about effectiveness
Nitrofurantoin100 mg two times per day for five days93Up to 1.6Glomerular filtration rate less than 40 to 60 mL per minute, history of cholestatic jaundice or hepatic dysfunction with previous use, pregnancy (greater than 38 weeks' gestation), pulmonary or hepatic fibrosis, suspected pyelonephritis; use with caution in patients with G6PD deficiencyFlatus, headache, hemolytic anemia, nausea, neuropathy; risk of pulmonary and hepatic fibrosis with long-term use$19 (NA)BMinimal change in gut flora; should be taken with meals; may turn urine orange; effective against E. faecalis, S. aureus, and Staphylococcus saprophyticusFive-day course is as effective as three-day course of trimethoprim/ sulfamethoxazole for treatment of acute cystitis
Trimethoprim/ sulfamethoxazole160/800 mg two times per day for three days93Up to 24.2History of drug-induced thrombocytopenia or other hematologic disorder, local resistance rates greater than 20%, pregnancy, sulfa allergy, use in previous three to six months; use with caution in patients with hepatic or renal impairment, porphyria, or G6PD deficiencyBone marrow suppression, electrolyte abnormalities, hepatotoxicity, nausea, nephrotoxicity, photosensitivity, rash, Stevens-Johnson syndrome$4 (NA)DAlters gut floraThree-day course is appropriate if local resistance rates do not exceed 20%
Second-line agents
Fluoroquinolones (e.g., ciprofloxacin, levofloxacin [Levaquin])
  • Ciprofloxacin: 250 mg two times per day for three days

  • Levofloxacin: 250 to 500 mg per day for three days

90
  • Ciprofloxacin: up to 17

  • Levofloxacin: up to 6

Concurrent use with medications that prolong QT interval, hypokalemia, hypomagnesemia, local resistance rates greater than 10%, myasthenia gravis, pregnancy; use with caution in patients with renal impairmentDiarrhea, drowsiness, headache, insomnia, nausea, QT interval prolongation, tendon rupture
  • Ciprofloxacin: $4 (NA)

  • Levofloxacin: $6 ($81 to $93)

CAlters gut flora; ciprofloxacin is preferred over other fluoroquinolones; limit use to patients with pyelonephritis or resistant cystitisThree-day course is highly effective for treatment of cystitis; reserve for treatment of more severe conditions (e.g., pyelonephritis)
Alternative agents if first- and second-line agents are contraindicated
Beta-lactams (e.g., amoxicillin/clavulanate [Augmentin], cefaclor, cefdinir, cefpodoxime, cephalexin [Keflex])
  • Amoxicillin/clavulanate: 500/125 mg two times per day for three days

  • Cefaclor: 250 mg three times per day for five days

  • Cefdinir: 300 mg two times per day for five days

  • Cefpodoxime: 100 mg two times per day for three days

  • Cephalexin: 500 mg two times per day for seven days

89Varies by medicationCephalosporin or penicillin allergy, history of cholestatic jaundice with previous use; use with caution in patients with renal or hepatic impairment, history of infectious colitis, or active mononucleosis; use cephalexin with caution in patients with elevated international normalized ratiosDiarrhea (including Clostridium difficile colitis), headache, hepatotoxicity, nausea, rash, vaginitis
  • Amoxicillin/clavulanate: $10 ($300)

  • Cefaclor: $28 (NA)

  • Cefdinir: $19 (NA)

  • Cefpodoxime: $21 (NA)

  • Cephalexin: $4 ($130)

BAlters gut flora; use with caution because of increasing prevalence of ESBL-producing Escherichia coliCourses of three to seven days are appropriate if other agents cannot be used; fewer supporting data for cephalexin; high resistance rates should preclude use of amoxicillin